Overview

Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC

Status:
Completed

Trial end date:
2013-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether low-dose peg-interferon plus ribavirin therapy is effective in the prevention of hepatocellular carcinoma (HCC) in patients who had the curative resection of primary HCC.

Phase:

Phase 4

Details

Lead Sponsor:

Kyoto University

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Ribavirin